Plain-English translation of NCT05535855 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new treatment called UCD19 CAR T cells for adults with a type of blood cancer called B-cell acute lymphoblastic leukemia (B-ALL) that is in remission but shows signs the disease may return. The treatment involves taking your own immune cells, engineering them in the laboratory to recognize and attack cancer cells, and then putting them back into your body. The study wants to understand if this treatment is safe and how well it works.
Even when blood cancer appears to be gone after chemotherapy, tiny amounts of cancer cells can remain and cause the disease to come back. This medication is designed to find and destroy those remaining cancer cells before they can regrow, potentially preventing relapse.
You likely qualify if…
You likely don't qualify if…
You will undergo a procedure called apheresis to collect your immune cells, which takes several hours. You will then receive chemotherapy to prepare your body for the new cells, followed by an infusion of your engineered CAR T cells back into your bloodstream. The study team will monitor you closely for the first 42 days and then at follow-up visits at months 3, 6, 12, and 24 to watch for side effects and measure how well the treatment works.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
United States